Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ilacirnon - ChemoCentryx

Next Previous
Drug Profile

Ilacirnon - ChemoCentryx

Alternative Names: CCX-140; CCX-140B; Ilacirnon sodium

Latest Information Update: 22 Feb 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ChemoCentryx
  • Developer ChemoCentryx; Vifor
  • Class 2 ring heterocyclic compounds; Antihyperglycaemics; Chlorobenzenes; Fluorinated hydrocarbons; Pyridines; Pyrimidines; Pyrroles; Small molecules; Sulfonamides; Urologics
  • Mechanism of Action CCR2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Focal segmental glomerulosclerosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Diabetic nephropathies
  • No development reported Kidney disorders; Type 2 diabetes mellitus
  • Discontinued Focal segmental glomerulosclerosis; Multiple sclerosis; Vascular restenosis

Most Recent Events

  • 06 Feb 2024 ChemoCentryx terminates the phase II LUMINA 2 trial for Focal Segmental Glomerulosclerosis in Poland and USA (EudraCT2017-003022-32) (NCT03703908)
  • 28 Jan 2021 No recent reports of development identified for research development in Kidney-disorders in USA (PO)
  • 18 May 2020 Discontinued - Phase-II for Focal segmental glomerulosclerosis in France, New Zealand, United Kingdom, New Zealand, Italy, Canada, Poland, Australia, USA (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top